



DETECT T1D: FROM AWARENESS TO ACTION:

Driving Multidisciplinary Application
of Screening and Disease Modifying
Therapies in Early Stage T1D

Speaker



Antoinette Moran, MD

Professor, Division Chief of
Pediatric Endocrinology and
Diabetes
University of Minnesota
Medical School
Minneapolis, Minnesota

Guidelines and Practice Parameters

RESOURCE	ADDRESS
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of care in diabetes—2025. <i>Diabetes Care</i> . 2025;48(suppl 1):S27-S49.	https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566
American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: Standards of care in diabetes—2025. <i>Diabetes Care</i> . 2025;48(suppl 1):S50-S58.	https://diabetesjournals.org/care/article/48/Supplement_1/S50/157550
Besser REJ, Bell KJ, Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. <i>Pediatr Diabetes</i> . 2022;23:1175-1187.	https://onlinelibrary.wiley.com/doi/10.1111/pedi.13410
Haller MJ, Bell KJ, Besser RE, et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, staging, and strategies to preserve beta cell function in children and adolescents with type 1 diabetes. <i>Horm Res Paediatr</i> . 2024;97:529-545.	https://karger.com/hrp/article/doi/10.1159/000543035/917924/ISPAD-Clinical-Practice-Consensus-Guidelines-2024
Mehta S, Ryabets-Lienhard A, Patel N, et al. Pediatric Endocrine Society statement on considerations for the use of teplizumab (TzielDTM) in clinical practice. <i>Horm Res Paediatr</i> . 2025;98:597-608.	https://karger.com/hrp/article/doi/10.1159/000538775/906682/Pediatric-Endocrine-Society-Statement-on
Philip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. <i>Diabetes Care</i> . 2024;47:1276-1298.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dci24-0042

References/Reading List

RESOURCE	ADDRESS
Atkinson MA, Mirmira RG. The pathogenic "symphony" in type 1 diabetes: A disorder of the immune system, β cells, and exocrine pancreas. <i>Cell Metab.</i> 2023;35:1500- 1518.	https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00228-0
Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. C peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet. <i>Diabetes Care.</i> 2020;43:1836-1842.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dc19-2288
Calhoun P, Spanbauer C, Steck AK, et al. Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development. <i>Diabetologia.</i> 2025;68:930-939.	https://link.springer.com/article/10.1007/s00125-025-06362-1
Felton JL, Tuttle A, Sims EK. Teplizumab-mzwv: Perspective on clinical practice use at a single institution. <i>J Precision Med.</i> 2025;2:e149-e157.	https://smart-md.org/index.php/jpm/article/view/20
Fyvie MJ, Gillespie KM. The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness. <i>Front Immunol.</i> 2023;14:1158278.	https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1158278/full
Galderisi A, Sims EK, Evans-Molina C, et al. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: Natural history and response to teplizumab. <i>Diabetologia.</i> 2025;68:646-661.	https://link.springer.com/article/10.1007/s00125-024-06323-0#citeas
Galderisi A, Carr ALJ, Martino M, et al. Quantifying beta cell function in the preclinical stages of type 1 diabetes. <i>Diabetologia.</i> 2023;66:2189-2199.	https://link.springer.com/article/10.1007/s00125-023-06011-5



RESOURCE	ADDRESS
Greenbaum CJ, Nepom GT, Wood-Heickman LK, et al. Evolving concepts in pathophysiology, screening, and prevention of type 1 diabetes: Report of diabetes mellitus interagency coordinating committee workshop. <i>Diabetes</i> . 2024;73:1780-1790.	https://diabetesjournals.org/diabetes/article-lookup/doi/10.2337/dbi24-0020
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. <i>N Engl J Med</i> . 2019;381:603-613.	https://www.nejm.org/doi/10.1056/NEJMoa1902226
Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: A disease-modifying therapy for type 1 diabetes that preserves β -Cell function. <i>Diabetes Care</i> . 2023;46:1848-1856.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dc23-0675
Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> . 2021;44:2589-2625.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dci21-0043
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care</i> . 2015;38:1964-1974.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dc15-1419
Jacobsen LM, Schatz D. Immunotherapy-based strategies for the treatment of type 1 diabetes. <i>Horm Res Paediatr</i> . 2025;98:425-434.	https://karger.com/hrp/article/doi/10.1159/000542002/914841/Immunotherapy-Based-Strategies-for-Treatment-of

RESOURCE	ADDRESS
Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. <i>Nat Rev Dis Primers</i> . 2017;3:17016.	https://www.nature.com/articles/nrdp201716
Leichter SB, Felton JL, Rasmussen CG, et al. Establishing screening programs for presymptomatic type 1 diabetes: Practical guidance for diabetes care providers. <i>J Clin Endocrinol Metab</i> . 2025;110:2371-2382.	https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgaf194/8103687
Leslie RD, Evans-Molina C, Freund-Brown J, et al. Adult-onset type 1 diabetes: Current understanding and challenges. <i>Diabetes Care</i> . 2021;44:2449-2456.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dc21-0770
O'Donovan AJ, Gorelik S, Nally LM. Shifting the paradigm of type 1 diabetes: A narrative review of disease modifying therapies. <i>Front Endocrinol (Lausanne)</i> . 2024;15:1477101.	https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1477101/full
O'Donnell HK, Rasmussen CG, Dong F, et al. Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes. <i>Diabetes Care</i> . 2023;46:2155-2161.	https://diabetesjournals.org/care/article-lookup/doi/10.2337/dc23-0350
O'Donnell HK, Simmons KM, Gitelman SE, et al. Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. <i>Diabetes Obes Metab</i> . 2025;27:2495-2506.	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.16246
Ospelt E, Hardison H, Rioles N, et al. Understanding providers' readiness and attitudes toward autoantibody screening: A mixed-methods study. <i>Clin Diabetes</i> . 2024;42:17-26.	https://diabetesjournals.org/clinical/article-lookup/doi/10.2337/cd23-0057
Mader JK, Wong JC, Freckmann G, et al. The use of continuous glucose monitoring to diagnose stage 2 type 1 diabetes. <i>J Diabetes Sci Technol</i> . 2025;19:1109-1127.	https://pubmed.ncbi.nlm.nih.gov/40444471/



RESOURCE	ADDRESS
Marzinotto I, Pittman DL, Williams AJK, et al. Islet Autoantibody Standardization Program: Interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops. <i>Diabetologia</i> . 2023;66:897-912.	https://pubmed.ncbi.nlm.nih.gov/36759347/
Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and β -Cell function in newly diagnosed type 1 diabetes. <i>N Engl J Med</i> . 2023;389:2151-2161.	https://www.nejm.org/doi/10.1056/NEJMoa2308743
Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: Where are we? <i>J Clin Endocrinol Metab</i> . 2023;108:3067-3079.	https://academic.oup.com/jcem/article/108/12/3067/7192350
Simmons KMW, Frohnert BI, O'Donnell HK, et al. Historical insights and current perspectives on the diagnosis and management of presymptomatic type 1 diabetes. <i>Diabetes Technol Ther</i> . 2023;25:790-799.	https://www.liebertpub.com/doi/10.1089/dia.2023.0276
Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: A status report and perspective. <i>Diabetes</i> . 2022;71:610-623.	https://diabetesjournals.org/diabetes/article-lookup/doi/10.2337/dbi20-0054
Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. <i>Sci Transl Med</i> . 2021;13:eabc8980.	https://www.science.org/doi/10.1126/scitranslmed.abc8980
Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. <i>Sci Transl Med</i> . 2021;13:eabc8980.	https://www.science.org/doi/10.1126/scitranslmed.abc8980
Sims EK, Cuthbertson D, Ferrat LA, et al. IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. <i>Diabetologia</i> . 2025;68:993-1004.	https://pubmed.ncbi.nlm.nih.gov/40016443/



RESOURCE	ADDRESS
Sooy M, Pyle L, Alonso GT, et al. Lower prevalence of diabetic ketoacidosis at diagnosis in research participants monitored for hyperglycemia. <i>J Clin Endocrinol Metab.</i> 2024;110:e80-e86.	https://pubmed.ncbi.nlm.nih.gov/38470864/

Resources and Societies

RESOURCE	ADDRESS
American Diabetes Association®. Summary of the American Diabetes Association® Type 1 Diabetes Screening & Awareness Roundtable. December 15, 2023.	https://diabetes.org/sites/default/files/2024-04/ADA-T1D-Screening-and-Awareness-Roundtable-Report.pdf
ASK (Autoimmunity Screening for Kids). T1D screening program.	https://www.askhealth.org/
Breakthrough T1DTM. Enrolling in Clinical Trials.	https://www.breakthrough1d.org/clinical-trials/
Breakthrough T1D. Type 1 Diabetes Early detection.	https://www.breakthrough1d.org/early-detection/
CASCADE Research Study. Type 1 diabetes and celiac disease screening for children in the state of Washington.	https://cascadekids.org/
Sanford Research. PLEDGE Pediatric Screening Study.	https://research.sanfordhealth.org/fields-of-research/diabetes/pledge



RESOURCE	ADDRESS
Type 1 Diabetes TrialNet. For Healthcare Providers: TrialNet Recommendations for Clinicians.	https://www.trialnet.org/healthcare-providers
Type 1 Diabetes TrialNet. Resources for T1D screening & national T1D screening program.	https://www.trialnet.org/
University of Colorado – Barbara Davis Center for Diabetes. Ask the experts for early T1D answers and guidance.	https://www.asktheexperts.org/
University of Colorado – Barbara Davis Center for Diabetes. Screen TO Prevent Type 1 Diabetes – stopT1D.	https://www.stopt1dprogram.org/

All URLs accessed October 1, 2025